Head-to-head · WeighScore
GOAL.MD vs LVNG RX
The verdict
GOAL.MD takes it — 68.6/100 to 62.5/100.
GOAL.MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GOAL.MD is a St. Louis-based telehealth platform offering compounded semaglutide alongside brand-name bridges to Ozempic, Wegovy, and Zepbound. Its standout is a manual-renewal model — no auto-billing
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | GOAL.MD | LVNG RX |
|---|---|---|
| WeighScore | 68.6/100 | 62.5/100 |
| Grade | C | C |
| Scorecard rank | #142 | #268 |
| Semaglutide | $179/mo | $149/mo (starting dose, compounded) |
| Tirzepatide | $249/mo (starting dose, compounded) | $249/mo (microdose tier, starting dose, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #142 · C
Strengths
- Transparent dose-tiered pricing on brand pens
- LegitScript Certified
- Manual-renewal model — no surprise auto-billing
- Free nutrition coach included
- BBB A+ rating since 2021
Where it loses points
- No named compounding pharmacy partner
- Co-founder and chief physician has a 2016 federal guilty plea for distributing misbranded HGH and a (reinstated) license revocation
- No URAC or PCAB pharmacy accreditation
Graded #268 · C
Strengths
- One bundled price covers the provider visit, prescription, shipping and ongoing check-ins, with zero consultation charges
- States you are charged nothing if a provider does not approve you for treatment
- Promises no dose-change surcharges — 'the price we quote is the price you pay, period'
- Semaglutide from $149/mo is competitive against the wider compounded market
- Offers a lower-dose GLP-1 microdose program alongside standard semaglutide and tirzepatide
Where it loses points
- Displays a Trustpilot 'Rated Excellent 4.8 / 5' badge, but no Trustpilot profile exists for the domain or the brand
- Also claims '4.9 based on 300+ Google reviews'; no Google listing for the business could be located
- Its own homepage figures conflict — '10k+' members in the hero versus '1,743+ patients supported' in the counters below
- The actual plan price is confirmed only after provider review, and the three treatment pages publish no prices at all
- No compounding pharmacy, medical group or individual clinician is named anywhere on the site
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.